Humacyte Inc (NASDAQ:HUMA) has a beta value of 1.58 and has seen 10.7 million shares traded in the last trading session. The company, currently valued at $262.00M, closed the last trade at $1.71 per share which meant it lost -$0.25 on the day or -13.01% during that session. The HUMA stock price is -483.04% off its 52-week high price of $9.97 and -2.92% below the 52-week low of $1.76. If we look at the company’s 10-day average daily trading volume, we find that it stood at 6.94 million shares traded. The 3-month trading volume is 2.97 million shares.
The consensus among analysts is that Humacyte Inc (HUMA) is Buy stock at the moment, with a recommendation rating of 1.29. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 1 out of 2 have rated it as a Hold, with 1 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -0.21.
Humacyte Inc (NASDAQ:HUMA) trade information
Sporting -13.01% in the red in last session, the stock has traded in the red over the last five days, with the highest price hit on recent trading when the HUMA stock price touched $1.71 or saw a rise of 44.84%. Year-to-date, Humacyte Inc shares have moved -66.24%, while the 5-day performance has seen it change -48.64%. Over the past 30 days, the shares of Humacyte Inc (NASDAQ:HUMA) have changed -49.85%. Short interest in the company has seen 26.6 million shares shorted with days to cover at 11.69.
Wall Street analysts have a consensus price target for the stock at $8, which means that the shares’ value could jump 78.62% from current levels. The projected low price target is $6.0 while the price target rests at a high of $10.0. In that case, then, we find that the current price level is -484.8% off the targeted high while a plunge would see the stock gain -250.88% from current levels.
Humacyte Inc (HUMA) estimates and forecasts
The company’s shares have lost -68.83% over the past 6 months. Revenue growth from the last financial year stood is estimated to be 0.00%.
5 analysts offering their estimates for the company have set an average revenue estimate of 457.8k for the current quarter. 5 have an estimated revenue figure of 1.17M for the next ending quarter.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 42.43% over the past 5 years.
HUMA Dividends
Humacyte Inc is expected to release its next earnings report on 2025-Mar-27 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Humacyte Inc (NASDAQ:HUMA)’s Major holders
Insiders own 22.76% of the company shares, while shares held by institutions stand at 29.65% with a share float percentage of 38.39%. Investors are also buoyed by the number of investors in a company, with Humacyte Inc having a total of 211.0 institutions that hold shares in the company. The top two institutional holders are BLACKROCK INC. with over 7.14 million shares worth more than $34.27 million. As of 2024-06-30, BLACKROCK INC. held 5.9912% of shares outstanding.
The other major institutional holder is VANGUARD GROUP INC, with the holding of over 4.73 million shares as of 2024-06-30. The firm’s total holdings are worth over $22.7 million and represent 4.3693% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and SPDR SERIES TRUST-SPDR(R) S&P(R) Biotech ETF . As of Dec 31, 2024 , the former fund manager holds about 1.79% shares in the company for having 2.59 shares of worth $4.42 million while later fund manager owns 2.45 shares of worth $4.18 million as of Feb 28, 2025 , which makes it owner of about 1.69% of company’s outstanding stock.
